Two FSHD Muscle Regeneration Compounds Enter Clinical Trials This Summer

The momentum in FSHD muscle regeneration research continues to grow.

Scholar Rock recently announced plans to launch its phase 2 FORGE clinical trial of apitegromab, a myostatin inhibitor designed to preserve and improve muscle strength and function, in people living with FSHD by mid-2026.

Now, NovMetaPharma has announced a new clinical development and licensing collaboration with FSHD Canada Foundation to advance Cyclo-Z, a first-in-class oral muscle-preserving therapy, into clinical development for FSHD.

Together, these announcements mark an exciting milestone, with two promising muscle regeneration treatments expected to enter clinical trials for FSHD this summer.

Learn more:

Scholar Rock: 

NovMetaPharma: